CD86 and melanoma: Melanoma CSCs displayed lower levels of MHC-I (but not MHC-II) and melanoma-associated antigens (e.g., MART-1, ML-IAP, NY-ESO-1, MAGE-A), while displayed higher levels of co-stimulatory molecules CD86 and PD-L1, responsible to their immune-evasive capacity [33].